We estimated the effect of XYKJP on inflammatory cytokines in colitis tissues and found that XYKJP treatment led to a reduction in the levels of IL-1β, TNF-α, and IL-6, and a significant improvement in the level of IL-10 and IL-22, as demonstrated by ELISA (Fig. 6A). Here, IL1B is linked to colitis.